Sign in
CADL Stock Price, Chart, Stats & News
Candel Therapeutics, Inc.
Save
467.21M
Market cap
–
Current P/E
43.48x
Forward P/E
CADL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -30.50% |
ROE | -51.44% |
D/E | 0.04x |
Interest coverage ratio | -22.78x |
CADL valuation
P/E | – |
P/S | – |
P/B | 5.09x |
P/CF | -6.89x |
P/FCF | -6.79x |
P/OCF | -6.89x |
PEG | 0.23x |
EV multiple | -8.05x |
About
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.
Similar securities
Based on sector and market capitalization
Report issue